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Purpose
Non-small cell lung carcinoma (NSCLC) comprises 75-85% of all lung cancers, and approximately
25% of all NSCLC patients develop brain metastasis. There are no reliable markers for predicting
in which patients this metastasis will occur. DCUN1D1, also known as squamous cell carcinoma-
related oncogene, is associated with tumor progression and poor outcomes in NSCLC. The ob-
jective of this study was to investigate the role of DCUN1D1 expression in cases of brain metastasis
due to NSCLC.
Materials and Methods
Primary tumor samples from a total of 71 cases of NSCLC, either with (n=40) or without (n=31)
brain metastasis, were evaluated for DCUN1D1 expression by immunohistochemistry analysis.
Results
DCUN1D1 expression was detected in 16 patients (23%) and tended to correlate with T classifi-
cation (15% of T1-2 tumors vs. 30% of T3-4 tumors, p=0.083). DCUN1D1 expression was significantly
associated with tumor stage. It was observed in none of the patients with stage I disease, 10% of
those with stage II disease, and 29% with stage III disease (p=0.009). In addition, 14 of 16 DCUN1D1-
positive patients resulted in brain metastasis (p=0.01). The odds ratio of brain metastasis for pa-
tients with DCUN1D1 expression was 3.112 (p=0.009).
Conclusion
DCUN1D1 expression may play a role in tumor progression and development of brain metastasis
in patients with NSCLC. Evaluation of DCUN1D1 expression may provide assistance in identifying
those patients who are at higher risk for brain metastasis.
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Introduction
Incidence rates of non-small cell lung carcinoma (NSCLC) are rising
worldwide while survival rates remain stagnant. Despite advances in can-
cer treatment, overall survival at 5 years after diagnosis of NSCLC is only
15%. NSCLC is frequently associated with brain metastasis during the
course of the illness [1]. Invasive progression and metastasis is a complex,
multi-step process which involves various interactions between tumor
cells and host tissues including alterations in tumor cell proliferation, ad-
hesion, proteolysis and invasion of the extracellular matrix, angiogenesis,
and colonization and growth at the target organ [2]. During progression,
tumor cells may acquire the ability to preferentially colonize particular
organs, such as the brain. Identification of the molecular factors involved
in brain metastasis from primary NSCLC is imperative, because overall
survival and quality of life will depend on the control of the metastasis as
the intrathoracic management of the locally advanced NSCLC improves.
Several studies have suggested that brain metastasis is related with p53,
Ki-67, and proteins mediating cell adhesion [3-6]. However, it remains
unclear which molecular and biological mechanisms are responsible for
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DCUN1D1, also known as squamous cell carcinoma-related oncogene,
is a novel gene initially identified as a result of investigation of 3q ampli-
fication in head and neck squamous cell carcinoma [7]. DCUN1D1-trans-
formed NIH-3T3 cells demonstrated a significantly higher invasive
capacity, both in vitro and in vivo [8-10]. The mechanism by which
DCUN1D1 expression induces extracellular matrix invasion may involve
activation of matrix metalloproteinase 2 transcription in an activator pro-
tein-2 and p53-dependent manner. In addition, DCUN1D1 expression is
correlated with vascular endothelial growth factor-A expression in lung
squamous cell carcinomas, implicating a role in angiogenesis [11-13].
In the present study, lung tumor samples obtained from NSCLC pa-
tients, either with or without evidence of brain metastasis, were subjected
to immunohistochemistry evaluation to examine DCUN1D1expression
and to determine its significance in the development of brain metastasis
from primary tumor(s).
M ater ials  and  Methods
1. Patient characteristics
A total of 71 NSCLC patients identified with primary tumors, either
adenocarcinoma or squamous cell carcinoma, from January 1, 2005 to
December 31, 2009, were included in this study. All patients were avail-
able for follow-up evaluation of clinical outcomes (40 with the brain as
the first site of metastasis and 31 without brain metastasis). None of the
patients had received therapy prior to the diagnosing biopsy performed at
our institution. Tumors were rated according to World Health Organization
(WHO) classifications, and staged according to the tumor-node-metastasis
staging system recommended by the American Joint Committee on Can-
cer. The study protocol was approved by the Institutional Review Board
of St. Vincent’s Hospital at The Catholic University of Korea (IRB No.
VC10SIS10030). Informed consent was waived by the Institutional Re-
view Board. Clinical information was obtained through a computerized
database of the tumor registry. Clinical follow-up for the patients in this
study was conducted until December 2010, for a time period ranging from
1 to 65 months, with a mean of 29 months. Brain metastases were docu-
mented by computed tomography or magnetic resonance imaging
records.
2. Immunohistochemical analysis
Tissue sections were obtained from 71 formalin-fixed, paraffin-em-
bedded NSCLC specimens. Immunohistochemical studies were per-
formed using a sensitive peroxidase-streptavidin method for the detection
of DCUN1D1 (GenWay Biotech, Inc., San Diego, CA), as described pre-
viously [14].
Briefly, 4 μm thick histology sections were placed on positively charged
slides, deparaffinized in xylene, and then rehydrated in graded alcohols
and water. The endogenous peroxidase activity was blocked by soaking
the slides in 3% H2O2at 45°C for 5 minutes. For antigen retrieval, the sec-
tions were immersed in a citrate buffer (2.1 g/L, pH 6.0) and then auto-
claved for 15 minutes. The slides were treated with a protein blocking
reagent before incubation overnight with primary antibody at a 1 : 100
dilution in a humidified chamber at 4°C, as recommended by the supplier.
After extensive washing with tris buffer, the immunoreactions were as-
sessed using the UltraVision LP detection system (Thermo Fisher Scien-
tific, Fremont, CA). Diaminobenzidine was used as a chromogen and
hematoxylin as a nuclear counterstain.
Tissue from the renal tubule was used as a positive control. The primary
antibody was omitted during processing to create the negative control. All
immunostained slides were examined independently by two experienced
pathologists (S.H.L. and K.I.L.) in a blind-fashion. The results of im-
munostaining against DCUN1D1 cytoplasmic expression were graded
by a scoring system where ‘N0’ indicated DCUN1D1 expression was ab-
sent, ‘N1’ indicated low expression, ‘N2’ indicated moderate expression,
and ‘N3’ indicated high levels of expression. Scores of 2 and 3 were con-
sidered ‘positive’ results.
3. Statistical analysis
Statistical analyses were carried out using the SPSS ver. 13.0 (SPSS
Inc, Chicago, IL). Correlations between clinicopathologic factors and
DCUN1D1 expression were estimated using Spearman’s chi-square and
Variables
No. of patients %
(n=71)
Mean age (yr) 61.4
Gender Male 50 70
female 21 30
Histology Adenocarcinoma 32 45
Squamous cell carcinoma 39 55
T classification T1 17 24
T2 24 34
T3 14 20
T4 16 23
N classification N0 23 32
N1 10 14
N2 19 27
N3 19 27
Stage at diagnosis I9 13
II 10 14
III 52 73
Brain metastasis Yes 40 56
No 31 44
DCUN1D1 Positive 16 23
Negative 55 77
Table 1. Patient characteristics and DCUN1D1 expression
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Fisher’s exact tests. Associations between brain metastasis and various
parameters were evaluated by the age-adjusted Mantel-Haenszel estimate
of the odds ratio. Two-sided p-values were determined with a log-rank
test. The level of significance was set at 0.05.
Results
A total of 50 men and 21 women ranging in age from 19 to 79 years
(mean age, 61.4 years) were included in this study (Table 1). Pathology
review confirmed histologic subtypes of adenocarcinoma in 32 patients
(45%) and squamous cell carcinoma in 39 patients (55%). The patients
were staged at time of diagnosis and 9 had stage I disease, 10 had stage II
disease, and 52 had stage III disease. Brain metastasis appeared in 40 pa-
tients (56%), 2-37 months after diagnosis. The negative and positive con-
trols produced expected results. All samples were investigated for
DCUN1D1expression, which was identified in 16 cases (23%) (Fig. 1).
DCUN1D1 expression was observed in 15% of T1-2 tumors and in
30% of T3-4 tumors (Table 2). This difference approached statistical sig-
nificance for a positive correlation (p=0.083). DCUN1D1 was more fre-
quently expressed in patients with N1-3 status than in patients with N0
status  (27%  vs.  13%),  but  no  statistical  significance  was  found.
DCUN1D1 expression was not detected in patients with stage I disease.
However, DCUN1D1 was expressed in 10% of patients with stage II dis-
ease and in 29% of patients with stage III disease (p=0/009). Of the 40
patients  who  developed  brain  metastasis,  14  (35%)  demonstrated
DCUN1D1 expression, whereas 2 of 31 (6%) with no evidence of brain
metastasis tested positive for DCUN1D1 immunoreactivity. This differ-
ence was statistically significant (p=0.01). Other clinicopathologic pa-
rameters including age, gender and histology, demonstrated no association
Table 2. Correlation between clinicopathologic factors and immunohistochemical profiles
Variables
DCUN1D1
Positive (%) Negative (%) p-value
Age (yr) 0.684
＜60 (n=30) 6 (21) 23 (79)
≥60 (n=41) 10 (24) 32 (76)
Gender 0.212
Male (n=50) 10 (20) 40 (80)
Female (n=21) 6 (29) 15 (71)
Histology 0.143
Adenocarcinoma (n=32) 5 (16) 27 (84)
Squamous cell carcinoma (n=39) 11 (28) 28 (72)
T classification 0.083
T1-2 (n=41) 6 (15) 35 (85)
T3-4 (n=30) 9 (30) 21 (70)
N classification 0.37
N0 (n=23) 3 (13) 20 (87)
N1-3 (n=48) 13 (27) 35 (73)
Stage at diagnosis 0.009
I (n=9) 0 (0) 9 (100)
II (n=10) 1 (10) 9 (90)
III (n=52) 15 (29) 37 (71)
Brain metastasis 0.01
No (n=31) 2 (6) 29 (94)
Yes (n=40) 14 (35) 26 (65)
Fig. 1. Immunohistochemistry results for DCUN1D1, showing cy-
toplasmic staining (ABCstaining, ￗ100).
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with DCUN1D1expression.
Table 3 presents the odds ratio for brain metastasis corresponding to
each variable. The risk of developing brain metastasis was low in patients
≥60 years in age compared to patients ＜60 years in age (odds ratio,
0.421; 95% confidence interval [CI], 0.214 to 0.827; p=0.012), and was
also low in patients with squamous cell carcinomas when compared to
patients with adenocarcinomas (odds ratio, 0.38; 95% CI, 0.191 to 0.761;
p=0.006). The hazard of brain metastasis for patients with positive
DCUN1D1 expression was 3.112 times that of patients with negative
DCUN1D1 expression (95% CI, 1.442 to 6.713; p=0.004). No significant
risk of developing brain metastasis was associated with gender (p=0.184).
Multivariate analysis revealed that DCUN1D1 expression was an inde-
pendent, unfavorable factor (Table 4).
Discussion
DCUN1D1 expression was assessed because of its well established
role in the metastatic process to other organs. Although specific molecular
abnormalities may be relevant to the occurrence of metastasis at other
sites, our study focused specifically on brain metastasis due to the prospect
of prophylactic cranial irradiation in NSCLC patients who receive adju-
vant chemoradiation. Furthermore, with advances in intrathoracic local
control of NSCLC, a favorable overall outcome increasingly depends on
early detection of brain metastasis. We compared patients who developed
brain metastasis with a control group of NSCLC patients who had no ev-
idence of brain metastasis during the 29 month mean follow-up period.
The two major findings of our study were as follows: 1) DCUN1D1 ex-
pression was associated with tumor progression as evidenced by its cor-
relation with T classification and tumor stage and 2) the brain as the initial
site of metastasis occurred in 88% (14/16) of patients with DCUN1D1-
positive tumors and in 47% (26/55) of DCUN1D1-negative patients
(p=0.01). The hazard ratio of brain metastasis increased approximately
threefold in patients with positive results for DCUN1D1 expression.
DCUN1D1 expression, or amplification, is observed in many malig-
nancies, with a predilection for squamous cell carcinomas of mucosal ori-
gin [7]. To date, only a few studies on the role of this gene in lung cancer
have appeared in the literature. DCUN1D1 was detected in 23% (16/71)
of our samples, which is lower than the prevalence of expression (50%)
reported in a previous study [15]. There are a few ways to address the dis-
crepancy in results between these studies. The difference in results may
be due to differences in the analytical methodologies used, as their study
was based on the analysis of DCUN1D1 mRNA levels while ours was
based on protein expression. In a study by Sarkaria et al. [10] using an
immunohistochemistry analysis method similar to the one used in our
work, the overall prevalence of DCUN1D1 expression in lung adenocar-
Table 3. Risk of developing brain metastasis according to clinicopathologic factors and DCUN1D1 expression
No. of patients
Variables Without brain With brain  OR (95% CI) p-value
metastasis (n=31) metastasis (n=40)
Age (yr) ＜60 (n=30) 8 22 1
≥60 (n=41) 23 18 0.421 (0.214-0.827) 0.012
Gender Male (n=50) 25 25 1
Female (n=21) 6 15 1.6 (0.800-3.200) 0.184
Histology Adenocarcinoma (n=32) 8 24 1
Squamous cell carcinoma (n=39) 23 16 0.38 (0.191-0.761) 0.006
DCUN1D1 Negative (n=55) 29 26 1
Positive (n=16) 2 14 3.112 (1.442-6.713) 0.004
OR, odds ratio; CI, confidence interval.
Table 4. Cox regression multivariate analysis
Variables Exp(B) 95% CI for Exp(B) p-value 
Age (yr) 0.584 0.282-1.221 0.148
Gender 1.081 0.472-2.472 0.854
Stage at diagnosis 6.379 0-269.336 0.965
Histology 0.461 0.193-1.102 0.082
DCUN1D1 2.41 1.118-5.194 0.007
CI, confidence interval.
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cinomas was 16.3%, which was consistent with our findings (16%). Other
factors, such as histologic subtype and progression (early vs. late) of the
tumors that were included in the studies may have played a role in the dif-
ference in study results. The specificity of 3q amplification in squamous
cell carcinomas has been indicated by comparative genomic hybridzation
analysis, which results in a higher frequency in squamous cell carcinomas
as compared to adenocarcinomas [7-10]. Results may vary according to
the proportion of tumor types included in the analysis. Our specimens
consisted of 39 squamous cell carcinomas and 32 adenocarcinomas, with
a higher prevalence of positive DCUN1D1 phenotype resulting in the
squamous cell carcinomas than in the adenocarcinomas (28% vs. 16%).
The previous study reporting 50% positivity in cases of NSCLC did not
divide the tumors into subtypes [15].
Our data demonstrated that the risk for brain metastasis for patients
with DCUN1D1 overexpression was 3.112 times higher than that of
DCUN1D1-negative patients. Furthermore, DCUN1D1 expression was
an independent parameter as observed by multivariate analysis and may
have value in identifying NSCLC patients who are at higher risk for brain
metastasis. However, we observed that 47% of DCUN1D1-negative pa-
tients also had brain metastasis. No differences in histology results or stage
were found in DCUN1D1-negative cases, with or without brain metasta-
sis. It is of interest that metastasis occurred more often in patients less than
60 years of age (69% vs. 31%). Based on our findings, age may attribute
to brain metastasis results. Metastasis to a distant organ location is a com-
plex, multistep process, and our study did not offer a fully objective view
because of the small sample sizes. Further studies with larger numbers of
the age-adjusted patients are needed.
To the best of our knowledge, this is the first report demonstrating the
association between DCUN1D1 expression and brain metastasis in lung
cancer. The exact mechanisms underlying this association are unclear.
However, DCUN1D1 has been shown to correlate with tumor progression
as revealed in the present study. Amplification of 3q has been reported to
be encountered in 3% of normal mucosa, 25% of carcinoma in situ, and
56% of invasive squamous cell carcinomas of the head and neck [13,15].
Similarly, studies using pure bronchioloalveolar carcinoma, bronchi-
oloalveolar carcinoma with focal invasion, and adenocarcinoma with
bronchioloalveolar carcinoma features, have found statistically significant
prevalence of DCUN1D1 expression in tumors with increasing degrees
of invasive components [10]. To metastasize to the brain, tumor cells must
adhere to the brain microvasculature, penetrate the blood-brain-barrier
(BBB), and grow within the brain parenchyma [4]. DCUN1D1-positive
tumor cells may have the ability to disrupt the BBB and colonize the brain.
Other studies have shown DCUN1D1-mediated glioma formation and
progression is associated with malignant glioblastoma [9]. Those findings,
as well as our data, suggest that DCUN1D1 may play a role in the brain
parenchyma invasion found in both primary brain tumors and metastatic
tumors. Investigations on several genes linked to these steps, along with
the downstream targets of DCUN1D1, are warranted. Such studies are
currently in progress at our laboratories.
C o nclusion
DCUN1D1 was associated with tumor progression and represented a
threefold increase in risk factor for brain metastasis, suggesting that
DCUN1D1- positive primary NSCLCs carry a biological predisposition
for metastasis to the brain. Measurement of DCUN1D1 protein may pro-
vide assistance in identifying those who are at higher risk for brain metas-
tasis. There is a need to conduct further studies on a larger scale for
validation of our results.
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